Analgesic efficacy of intravenous lacosamide administered perioperatively for thoracic surgery with thoracotomy approach. - LACO15

Javier E. Morales Sarabia0 个研究点开始时间: 2016年9月26日最近更新: 2017年2月20日

试验速览

暂无简介。

•- Patients over 18 years and less than or equal to 75 years.
•- Patients undergoing thoracic surgery for non-small cell lung cancer (NSCLC) with curative intent or resection of lung metastases by thoracotomy.
•- Patients ASA I-III.
•- Signature of informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Patient refusal.
•- Other diseases that warrant its non-inclusion according to medical criteria: severe renal disease (stage 3 and 4), liver disease (stages B and C ChildPugh) or psychiatric, heart rhythm disorders, bleeding disorders, pregnancy and lactation.
•- Lacosamide allergy, NSAIDs, local anesthetics and / or morphic.
•- Alcoholism.
•- Drug addiction.
•- Concurrent use of opioid analgesics or anti-epileptic type in the immediate preoperative period.
•- History of epilepsy or any neurological condition that needs treatment with lacosamide or other antiepileptic drug.
•- Functional status ASA> III.
•- Inability to understand the pain assessment scales.
•- Surgery that does not involve thoracotomy (pure thoracoscopic surgery or VATS).
•previous thoracotomy.
•- Pathology affecting the chest wall (locally invasive lung cancer, empyema thoracis necessitans, intercostal neural lesions, pathological fractures rib).
•- Surgery involving extensive involvement of the parietal pleura (such as pleurodesis, pleurectomy, extrapleural resection of the tumor).
•- Closing technique with metallic suture points.

发起方

Javier E. Morales Sarabia